Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Celon PharmaLTS:0RKX 21 Debt-to-EBITDA is 0.08 as of Mar. 2026, which is 88% below its 10-year median of 0.66. GuruFocus rates LTS:0RKX with a GF Score™ of 21/100. The stock has 3 warning signs investors should review. Among 687 Drug Manufacturers companies, Celon Pharma ranks better than 78.02% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Celon Pharma's Debt-to-EBITDA or its related term are showing as below:
LTS:0RKX'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.06 Med: 0.66 Max: 2.88
Current: 0.28
During the past 11 years, the highest Debt-to-EBITDA Ratio of Celon Pharma was 2.88. The lowest was 0.06. And the median was 0.66.
LTS:0RKX's Debt-to-EBITDA is ranked better than 78.02% of 687
companies
in the Drug Manufacturers industry
Industry Median: 1.64
vs LTS:0RKX: 0.28
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Celon Pharma Debt-to-EBITDA Related Terms
Celon Pharma Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Celon Pharma's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0RKX vs ZTS, UTHR, VTRS: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Celon Pharma's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celon Pharma Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Celon Pharma's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Celon Pharma's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Celon Pharma (LTS:0RKX) has a Debt-to-EBITDA of 0.08 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Celon Pharma. This is 88% below median its historical median of 0.66. Over the past decade, Celon Pharma's Debt-to-EBITDA has ranged from 0.06 to 2.88. According to the industry distribution chart, Celon Pharma ranks #151 out of 687 companies in the Drug Manufacturers industry, placing it in the top 22%.
Is Celon Pharma's Debt-to-EBITDA too high?
Celon Pharma's current Debt-to-EBITDA of 0.08 is 88% below median its 10-year median of 0.66. Over the past 10 years, this metric has ranged from a low of 0.06 to a high of 2.88. The Drug Manufacturers industry median Debt-to-EBITDA is 1.64. Celon Pharma's value of 0.08 is 95.1% below this industry median. Based on the distribution chart, Celon Pharma ranks #151 out of 687 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Celon Pharma has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Celon Pharma's Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Celon Pharma ranks #151 out of 687 companies for Debt-to-EBITDA. This places Celon Pharma in the top 22% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.64. Celon Pharma's value of 0.08 is 95.1% below this benchmark. Historically, Celon Pharma's own Debt-to-EBITDA has ranged from 0.06 to 2.88 over the past decade. While the company's 10-year median is 0.66 vs. the industry median of 1.64, Celon Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.64, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Celon Pharma's current Debt-to-EBITDA of 0.08 is 95.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Celon Pharma. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celon Pharma's current Debt-to-EBITDA is 0.08, which is 88% below median its own 10-year median of 0.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celon Pharma stock overvalued right now?
Celon Pharma (LTS:0RKX) has a current Debt-to-EBITDA of 0.08. The current Debt-to-EBITDA is 0.08, which is 88% below median its 10-year median of 0.66 and 95.1% below the Drug Manufacturers industry median of 1.64. Celon Pharma's overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Celon Pharma (LTS:0RKX), the current Debt-to-EBITDA is 0.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
21GF Score
Get the complete analysis for LTS:0RKX
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RKX has been successfully added to your 
